Differences_NNS in_IN the_DT N_NP Termini_NP of_IN Herpes_NP Simplex_NP Virus_NP Type_NP 1_CD and_CC 2_CD gDs_NNS That_DT Influence_NP Functional_NP Interactions_NP with_IN the_DT Human_NP Entry_NP Receptor_NP Nectin-2_NP and_CC an_DT Entry_NP Receptor_NP Expressed_NP in_IN Chinese_NP Hamster_NP Ovary_NP Cells_NP Amino_NP acid_NN differences_NNS at_IN seven_CD positions_NNS in_IN the_DT N_NP termini_NNS of_IN the_DT glycoproteins_NNS D_NN (_( gDs_NNS )_) specified_VBN by_IN herpes_NN simplex_JJ virus_NN type_NN 1_CD (_( HSV-1_NP )_) and_CC HSV-2_NP are_VBP largely_RB responsible_JJ for_IN the_DT significantly_RB higher_JJR cell_NN fusion_NN activity_NN of_IN HSV-2_JJ gD_NNS with_IN Chinese_JJ hamster_NN ovary_NN cells_NNS expressing_VBG human_JJ nectin-2_NN or_CC only_RB an_DT endogenous_JJ hamster_NN receptor_NN ._SENT Herpes_NN simplex_JJ virus_NN type_NN 1_CD (_( HSV-1_NP )_) and_CC HSV-2_NP cause_VBP mucocutaneous_JJ lesions_NNS that_WDT are_VBP indistinguishable_JJ clinically_RB ,_, but_CC the_DT two_CD serotypes_NNS exhibit_VBP differences_NNS in_IN gene_NN sequences_NNS ,_, biology_NN ,_, pathogenesis_NN ,_, and_CC epidemiology_NN ._SENT In_IN addition_NN ,_, the_DT two_CD serotypes_NNS exhibit_VBP some_DT differences_NNS in_IN the_DT efficiency_NN of_IN cell_NN entry_NN ,_, dependent_JJ on_IN the_DT entry_NN receptors_NNS expressed_VBD ,_, as_RB outlined_VBN below_RB ._SENT Heparan_JJ sulfate_NN chains_NNS on_IN cell_NN surface_NN proteoglycans_NNS provide_VBP initial_JJ binding_JJ sites_NNS for_IN both_DT HSV-1_NP and_CC HSV-2_NP ,_, but_CC each_DT serotype_NN recognizes_VBZ somewhat_RB different_JJ structural_JJ features_NNS of_IN heparan_JJ sulfate_NN ._SENT After_IN the_DT binding_NN of_IN HSV-1_NP or_CC HSV-2_NP to_TO heparan_JJ sulfate_NN ,_, another_DT viral_JJ glycoprotein_NN ,_, glycoprotein_NN D_NP (_( gD_NN )_) ,_, engages_VBZ any_DT one_CD of_IN several_JJ cell_NN surface_NN receptors_NNS to_TO initiate_VB the_DT process_NN of_IN viral_JJ entry_NN ._SENT Viral_JJ entry_NN occurs_VBZ by_IN fusion_NN of_IN the_DT viral_JJ envelope_NN with_IN a_DT cell_NN membrane_NN and_CC requires_VBZ the_DT envelope_NN glycoproteins_NNS gB_NN ,_, gH_NNS ,_, and_CC gL_NN ,_, as_RB well_RB as_IN gD_NN ,_, and_CC a_DT gD_JJ receptor_NN on_IN the_DT cell_NN ._SENT The_DT human_JJ HSV_NP gD_NN receptors_NNS include_VBP herpesvirus_NN entry_NN mediator_NN (_( HVEM_NP )_) ,_, a_DT member_NN of_IN the_DT tumor_NN necrosis_NN factor_NN receptor_NN family_NN ;_: nectin-1_JJ and_CC nectin-2_JJ ,_, members_NNS of_IN the_DT immunoglobulin_NN superfamily_NN that_WDT are_VBP cell_NN adhesion_NN molecules_NNS present_JJ in_IN cadherin-based_JJ adherens_NNS junctions_NNS ;_: and_CC sites_NNS in_IN heparan_JJ sulfate_NN generated_VBN by_IN the_DT action_NN of_IN specific_JJ 3-O-sulfotransferases_NNS ._SENT HSV-1_NP and_CC HSV-2_NP differ_VBP in_IN their_PP$ ability_NN to_TO use_VB the_DT various_JJ gD_NN receptors_NNS for_IN viral_JJ entry_NN ._SENT Human_NP HVEM_NP or_CC nectin-1_NP can_MD serve_VB as_IN entry_NN receptors_NNS for_IN both_DT serotypes_NNS ,_, whereas_IN nectin-2_NN has_VBZ a_DT higher_JJR entry_NN activity_NN for_IN HSV-2_JJ strains_NNS than_IN for_IN HSV-1_JJ strains_NNS ,_, and_CC 3-O-sulfated_JJ heparan_JJ sulfate_NN has_VBZ a_DT higher_JJR entry_NN activity_NN for_IN HSV-1_JJ strains_NNS than_IN for_IN HSV-2_JJ strains_NNS ._SENT Also_RB ,_, Chinese_JJ hamster_NN ovary_NN (_( CHO_NP )_) cells_NNS express_VBP an_DT endogenous_JJ receptor_NN for_IN HSV-2_NP entry_NN that_WDT has_VBZ only_RB minimal_JJ activity_NN for_IN HSV-1_JJ entry_NN ._SENT The_DT activity_NN of_IN the_DT HSV_NP entry_NN receptors_NNS can_MD be_VB assessed_VBN by_IN quantitative_JJ viral_JJ entry_NN assays_NNS ,_, as_RB well_RB as_IN by_IN quantitative_JJ cell_NN fusion_NN assays_NNS in_IN which_WDT cells_NNS expressing_VBG HSV_NP gB_NN ,_, gD_NNS ,_, gH_NNS ,_, and_CC gL_NN are_VBP tested_VBN for_IN their_PP$ ability_NN to_TO fuse_VB with_IN cells_NNS bearing_VBG entry/fusion_NN receptors_NNS ._SENT The_DT activities_NNS of_IN the_DT viral_JJ glycoproteins_NNS can_MD be_VB assessed_VBN similarly_RB by_IN using_VBG mutant_JJ viruses_NNS in_IN viral_JJ entry_NN assays_NNS or_CC mutant_JJ forms_NNS of_IN the_DT viral_JJ glycoproteins_NNS in_IN cell_NN fusion_NN assays_NNS ._SENT The_DT purpose_NN of_IN the_DT present_JJ study_NN was_VBD to_TO define_VB the_DT viral_JJ determinants_NNS responsible_JJ for_IN the_DT greater_JJR ability_NN of_IN HSV-2_NP ,_, compared_VBN to_TO wild-type_NP HSV-1_NP ,_, to_TO interact_VB functionally_RB with_IN human_JJ nectin-2_NN and_CC the_DT endogenous_JJ CHO_NP receptor_NN ._SENT 2_CD gD_NN confers_VBZ enhanced_JJ fusion_NN activity_NN with_IN the_DT CHO_NP receptor_NN and_CC nectin-2_NN ._SENT :_: Since_IN gD_NN is_VBZ the_DT ligand_NN for_IN all_DT known_JJ HSV_NP entry_NN receptors_NNS ,_, it_PP seemed_VBD likely_RB that_IN HSV-2_NP gD_NN determines_VBZ the_DT enhanced_JJ fusion_NN activity_NN of_IN HSV-2_JJ glycoproteins_NNS with_IN the_DT CHO_NP receptor_NN and_CC nectin-2_NN ._SENT To_TO test_VB this_DT hypothesis_NN ,_, quantitative_JJ cell_NN fusion_NN assays_NNS were_VBD done_VBN with_IN the_DT homologous_JJ set_NN of_IN HSV-1_NP or_CC HSV-2_NP glycoproteins_NNS or_CC with_IN mixtures_NNS in_IN which_WDT each_DT of_IN the_DT glycoproteins_NNS in_IN the_DT HSV-1_NP or_CC HSV-2_NP set_NN was_VBD substituted_VBN with_IN its_PP$ heterologous_JJ counterpart_NN ._SENT CHO_NP cells_NNS were_VBD transfected_VBN with_IN plasmids_NNS expressing_VBG the_DT appropriate_JJ mixtures_NNS of_IN HSV_NP glycoproteins_NNS and_CC T7_JJ polymerase_NN (_( termed_VBN effector_NN cells_NNS )_) ._SENT The_DT plasmids_NNS used_VBN for_IN expression_NN of_IN the_DT HSV-1(KOS)_NP glycoproteins_NNS were_VBD previously_RB described_VBN ._SENT A_DT number_NN of_IN plasmids_NNS were_VBD generated_VBN for_IN the_DT present_JJ study_NN ,_, as_RB described_VBN in_IN Table_NP ,_, and_CC the_DT inserts_NNS were_VBD sequenced_JJ to_TO confirm_VB the_DT desired_VBN coding_VBG of_IN amino_NN acid_NN sequence_NN ._SENT CHO_NN cells_NNS stably_RB expressing_VBG HVEM_NP ,_, nectin-1_JJ ,_, or_CC nectin-2_NN or_CC control_VB CHO_NP cells_NNS were_VBD transfected_VBN with_IN a_DT plasmid_NN carrying_VBG the_DT firefly_NN luciferase_NN gene_NN linked_VBN to_TO a_DT T7_JJ promoter_NN (_( termed_VBN target_NN cells_NNS )_) ._SENT The_DT effector_NN and_CC target_NN cells_NNS were_VBD then_RB mixed_VBN in_IN 1:1_CD ratios_NNS ,_, plated_VBN ,_, and_CC incubated_VBD for_IN 18_CD h_NN prior_JJ to_TO lysis_NN for_IN quantitation_NN of_IN luciferase_NN as_IN a_DT measure_NN of_IN cell_NN fusion_NN ._SENT Figure_NN shows_VBZ that_IN the_DT homologous_JJ mixtures_NNS of_IN HSV-1_NP and_CC HSV-2_NP glycoproteins_NNS induced_VBD levels_NNS of_IN cell_NN fusion_NN with_IN each_DT receptor_NN consistent_JJ with_IN viral_JJ entry_NN assays_NNS done_VBN with_IN the_DT same_JJ receptors_NNS ._SENT The_DT cell_NN fusion_NN assay_NN may_MD be_VB more_RBR sensitive_JJ in_IN that_DT HSV-1_NP glycoproteins_NNS exhibited_VBD low_JJ but_CC detectable_JJ activities_NNS with_IN the_DT endogenous_JJ CHO_NP receptor_NN and_CC nectin-2_NN ,_, whereas_IN HSV-1(KOS)_NP entry_NN with_IN these_DT receptors_NNS is_VBZ more_RBR difficult_JJ to_TO detect_VB ._SENT Figure_NN also_RB shows_VBZ that_DT substitution_NN of_IN HSV-1_JJ gD_NNS (_( gD1_JJ )_) with_IN gD2_NN in_IN the_DT otherwise_RB HSV-1_JJ set_NN significantly_RB enhanced_VBN cell_NN fusion_NN with_IN target_NN cells_NNS expressing_VBG the_DT CHO_NP receptor_NN only_RB or_CC also_RB nectin-2_JJ but_CC not_RB with_IN target_NN cells_NNS expressing_VBG nectin-1_JJ or_CC HVEM_NP ._SENT In_IN the_DT converse_JJ combination_NN ,_, substitution_NN of_IN gD2_NN with_IN gD1_NN in_IN the_DT otherwise_RB HSV-2_JJ set_NN significantly_RB reduced_VBN cell_NN fusion_NN with_IN the_DT CHO_NP receptor_NN and_CC nectin-2_JJ but_CC not_RB with_IN nectin-1_JJ or_CC HVEM_NP ._SENT Thus_RB ,_, gD_NN is_VBZ the_DT major_JJ determinant_NN of_IN the_DT differential_JJ ability_NN of_IN HSV-1_NP and_CC HSV-2_NP glycoproteins_NNS to_TO induce_VB cell_NN fusion_NN with_IN the_DT CHO_NP receptor_NN and_CC nectin-2_NN ._SENT Other_JJ findings_NNS emerged_VBD from_IN the_DT results_NNS presented_VBN in_IN Fig._NN ._SENT Substitution_NN of_IN gB2_NN with_IN gB1_NN in_IN the_DT HSV-2_NP set_VBD significantly_RB enhanced_JJ fusion_NN ,_, but_CC only_RB with_IN target_NN cells_NNS expressing_VBG nectin-1_JJ and_CC HVEM_NP ,_, whereas_IN substitution_NN of_IN gB1_NN with_IN gB2_NN in_IN the_DT HSV-1_NP set_NN reduced_VBD cell_NN fusion_NN with_IN target_NN cells_NNS expressing_VBG any_DT of_IN the_DT receptors_NNS ._SENT It_PP has_VBZ been_VBN reported_VBN that_IN deletions_NNS from_IN the_DT cytoplasmic_JJ C_NP terminus_NN of_IN gB2_NN can_MD enhance_VB cell_NN fusion_NN induced_VBN by_IN HSV-2_JJ glycoproteins_NNS with_IN cells_NNS in_IN which_WDT the_DT fusion_NN receptors_NNS were_VBD not_RB identified_VBN and_CC that_IN the_DT effect_NN was_VBD not_RB necessarily_RB correlated_VBN with_IN altered_JJ cell_NN surface_NN expression_NN of_IN this_DT glycoprotein_NN ._SENT We_PP have_VBP confirmed_VBN these_DT findings_NNS and_CC showed_VBD further_RBR that_DT substitution_NN of_IN wild-type_NN gB2_NN with_IN truncated_JJ gB2_NN had_VBD the_DT same_JJ effect_NN on_IN cell_NN fusion_NN with_IN nectin-1_NP and_CC HVEM_NP (_( A._NP Zago_NP and_CC P._NP G._NP Spear_NP ,_, unpublished_JJ results_NNS )_) ,_, as_RB did_VBD substitution_NN with_IN gB1_NN ._SENT It_PP seems_VBZ likely_RB that_IN the_DT cytoplasmic_JJ tail_NN of_IN wild-type_NN gB2_NN has_VBZ a_DT domain_NN that_WDT is_VBZ inhibitory_JJ for_IN cell_NN fusion_NN ,_, at_IN least_JJS with_IN certain_JJ fusion_NN receptors_NNS ,_, whereas_IN such_PDT an_DT inhibitory_JJ activity_NN in_IN wild-type_NN gB1_NN is_VBZ not_RB so_RB evident_JJ ._SENT The_DT greater_JJR ability_NN of_IN HSV-1_JJ glycoproteins_NNS ,_, compared_VBN to_TO HSV-2_JJ glycoproteins_NNS ,_, to_TO induce_VB cell_NN fusion_NN with_IN nectin-1_NP and_CC HVEM_NP is_VBZ probably_RB accounted_VBN for_IN by_IN this_DT inhibitory_JJ domain_NN in_IN gB2_NN ._SENT We_PP chose_VBD to_TO use_VB wild-type_NN gB2_NN in_IN the_DT present_JJ study_NN ._SENT Substitutions_NNS of_IN gH_NN and_CC gL_NN were_VBD not_RB done_VBN separately_RB because_IN these_DT glycoproteins_NNS are_VBP known_VBN to_TO function_VB as_IN a_DT heterodimer_NN ._SENT With_IN nectin-1_NP and_CC HVEM_NP ,_, substitutions_NNS of_IN gH/gL_NN in_IN either_DT combination_NN with_IN the_DT other_JJ glycoproteins_NNS had_VBD little_JJ effect_NN on_IN cell_NN fusion_NN ._SENT The_DT same_JJ was_VBD true_JJ for_IN the_DT CHO_NP receptor_NN and_CC nectin-2_NN when_WRB gH1/gL1_NN was_VBD substituted_VBN with_IN gH2/gL2_NN ._SENT However_RB ,_, substitution_NN of_IN gH2/gL2_NN with_IN gH1/gL1_NN in_IN the_DT otherwise_RB HSV-2_JJ mixture_NN reduced_VBD cell_NN fusion_NN activity_NN with_IN the_DT CHO_NP receptor_NN and_CC nectin-2_NN ._SENT This_DT phenomenon_NN requires_VBZ further_JJR exploration_NN beyond_IN the_DT scope_NN of_IN the_DT present_JJ study_NN ._SENT 2_LS ._SENT :_: Plasmids_NNS expressing_VBG hybrid_JJ forms_NNS of_IN gD_NNS were_VBD constructed_VBN ._SENT These_DT hybrids_NNS had_VBD the_DT first_JJ 66_CD or_CC 98_CD amino_NN acids_NNS from_IN gD1_JJ or_CC gD2_JJ and_CC the_DT remainder_NN from_IN gD2_JJ or_CC gD1_JJ ,_, respectively_RB ._SENT Plasmids_NNS expressing_VBG the_DT hybrid_JJ proteins_NNS were_VBD used_VBN in_IN cell_NN fusion_NN assays_NNS ,_, along_RB with_IN plasmids_NNS expressing_VBG the_DT wild-type_NN forms_NNS of_IN gD1_JJ or_CC gD2_JJ ,_, in_IN combination_NN with_IN the_DT other_JJ HSV-1_NP or_CC HSV-2_NP glycoproteins_NNS ._SENT The_DT results_NNS presented_VBN in_IN Fig._NN show_VBP that_IN the_DT gD2/1_JJ hybrid_NN having_VBG the_DT first_JJ 66_CD amino_NN acids_NNS from_IN HSV-2_NP resembled_VBD gD2_NN in_IN its_PP$ enhancement_NN of_IN fusion_NN with_IN target_NN cells_NNS expressing_VBG the_DT CHO_NP receptor_NN only_RB or_CC also_RB nectin-2_JJ when_WRB combined_VBN with_IN the_DT HSV-1_JJ glycoproteins_NNS ._SENT The_DT activity_NN of_IN the_DT gD2/1_JJ hybrid_NN was_VBD ca_MD ._SENT 60_CD to_TO 80_CD %_NN that_WDT observed_VBD with_IN gD2_NN regardless_RB of_IN whether_IN the_DT other_JJ glycoproteins_NNS were_VBD from_IN HSV-1_NP or_CC HSV-2_NP and_CC regardless_RB of_IN receptor_NN (_( except_IN that_IN the_DT gD2/1_JJ hybrid_NN had_VBD activity_NN comparable_JJ to_TO that_DT of_IN gD2_NN when_WRB the_DT receptors_NNS were_VBD nectin-1_JJ or_CC HVEM_NP and_CC the_DT other_JJ glycoproteins_NNS were_VBD from_IN HSV-2_NP )_) ._SENT Also_RB ,_, the_DT converse_JJ gD1/2_NN hybrid_NN resembled_VBD gD1_JJ in_IN its_PP$ poor_JJ cell_NN fusion_NN activity_NN with_IN target_NN cells_NNS expressing_VBG the_DT CHO_NP receptor_NN only_RB or_CC also_RB nectin-2_JJ when_WRB combined_VBN with_IN either_CC the_DT HSV-1_NP or_CC HSV-2_NP glycoproteins_NNS ._SENT The_DT gD1/2_JJ hybrid_NN was_VBD slightly_RB more_RBR active_JJ than_IN the_DT gD2/1_JJ hybrid_NN with_IN the_DT other_JJ HSV-1_JJ glycoproteins_NNS and_CC slightly_RB less_RBR active_JJ with_IN the_DT other_JJ HSV-2_NP glycoproteins_NNS when_WRB the_DT receptors_NNS were_VBD nectin-1_JJ and_CC HVEM_NP ._SENT Results_NNS similar_JJ to_TO those_DT shown_VBN in_IN Fig._NN for_IN CHO_NP cells_NNS were_VBD also_RB obtained_VBN with_IN hybrids_NNS in_IN which_WDT the_DT first_JJ 98_CD amino_NN acids_NNS were_VBD switched_VBN ._SENT We_PP conclude_VBP from_IN these_DT results_NNS (_( i_NP )_) that_IN the_DT hybrids_NNS had_VBD no_DT gross_JJ conformational_JJ abnormalities_NNS and_CC had_VBD fusion_NN activities_NNS comparable_JJ to_TO those_DT of_IN gD1_JJ and_CC gD2_JJ ,_, at_IN least_JJS when_WRB tested_VBN with_IN gB2_NN and_CC gH2/gL2_NN and_CC the_DT fusion_NN receptors_NNS ,_, nectin-1_JJ and_CC HVEM_NP ,_, and_CC (_( ii_NNS )_) that_IN the_DT superior_JJ activity_NN of_IN gD2_NN in_IN fusion_NN activity_NN with_IN the_DT CHO_NP receptor_NN and_CC nectin-2_NN is_VBZ largely_RB due_JJ to_TO amino_NN acid_NN differences_NNS between_IN gD2_JJ and_CC gD1_JJ within_IN the_DT first_JJ 66_CD amino_NN acids_NNS ._SENT Figure_NN shows_VBZ an_DT alignment_NN of_IN the_DT amino_NN acid_NN sequences_NNS of_IN gD1_JJ and_CC gD2_JJ in_IN the_DT first_JJ 66_CD amino_NN acids_NNS ._SENT There_EX are_VBP seven_CD differences_NNS in_IN sequence_NN ,_, five_CD of_IN which_WDT are_VBP also_RB noted_VBN on_IN a_DT backbone_NN trace_NN of_IN the_DT structure_NN of_IN gD1_NN ._SENT For_IN the_DT five_CD positions_NNS most_RBS likely_JJ to_TO affect_VB secondary_JJ and_CC tertiary_JJ structure_NN (_( i.e._FW ,_, positions_NNS 7_CD ,_, 21_CD ,_, 42_CD ,_, 43_CD and_CC 45_CD )_) ,_, gD1_NN was_VBD mutated_VBN by_IN substituting_VBG the_DT amino_NN acid_NN present_NN in_IN gD1_NN for_IN the_DT one_CD present_NN in_IN gD2_NN ._SENT These_DT substitutions_NNS were_VBD made_VBN individually_RB and_CC in_IN pairs_NNS (_( A7P_NP ,_, A7P/P45E_NP ,_, A7P/D21N_NP ,_, A42P/G43S_NP ,_, and_CC P45E_NNS )_) ._SENT When_WRB these_DT mutant_JJ forms_NNS of_IN gD1_NN were_VBD tested_VBN for_IN ability_NN to_TO induce_VB the_DT fusion_NN of_IN target_NN cells_NNS expressing_VBG the_DT CHO_NP receptor_NN only_RB or_CC also_RB nectin-2_JJ ,_, none_NN exhibited_VBD as_RB high_JJ as_IN 50_CD %_NN of_IN the_DT activity_NN observed_VBD with_IN gD2_NN ,_, using_VBG either_CC the_DT HSV-1_NP or_CC HSV-2_NP forms_NNS of_IN gB_NN and_CC gH/gL_NN ,_, except_IN in_IN the_DT case_NN of_IN the_DT HSV-1_JJ set_NN of_IN glycoproteins_NNS tested_VBN with_IN target_NN cells_NNS expressing_VBG only_RB the_DT CHO_NP receptor_NN ._SENT Only_RB the_DT gD1_JJ mutants_NNS carrying_VBG the_DT A7P_NP substitution_NN ,_, either_CC alone_RB or_CC in_IN combination_NN with_IN P45E_NP or_CC D21N_NP ,_, exhibited_VBD enhanced_JJ cell_NN fusion_NN activity_NN (_( 50_CD to_TO 60_CD %_NN that_IN of_IN gD2_NN )_) under_IN these_DT conditions_NNS (_( data_NNS not_RB shown_VBN )_) ._SENT None_NN of_IN the_DT gD1_JJ mutants_NNS tested_VBN with_IN either_DT HSV-1_NP or_CC HSV-2_NP gB_NN and_CC gH/gL_NN differed_VBD significantly_RB from_IN wild-type_NN gD1_NN in_IN cell_NN fusion_NN activity_NN when_WRB the_DT receptors_NNS were_VBD nectin-1_JJ or_CC HVEM_JJ (_( data_NNS not_RB shown_VBN )_) ._SENT We_PP conclude_VBP that_IN the_DT A7P_NP substitution_NN in_IN gD2_NN contributes_VBZ to_TO the_DT higher_JJR level_NN of_IN fusion_NN activity_NN of_IN gD2_NN but_CC that_IN multiple_JJ substitutions_NNS within_IN the_DT first_JJ 53_CD amino_NN acids_NNS of_IN gD2_NN (_( the_DT domain_NN containing_VBG all_DT of_IN the_DT differences_NNS between_IN gD1_JJ and_CC gD2_JJ in_IN the_DT first_JJ 66_CD amino_NN acids_NNS )_) ,_, including_VBG A7P_NP ,_, are_VBP required_VBN for_IN the_DT gD2-like_JJ levels_NNS of_IN cell_NN fusion_NN activity_NN with_IN the_DT CHO_NP receptor_NN and_CC nectin-2_NN ._SENT The_DT levels_NNS of_IN gD_NNS expressed_VBN on_IN the_DT surfaces_NNS of_IN glycoprotein-expressing_NN cells_NNS used_VBN in_IN the_DT cell_NN fusion_NN assays_NNS were_VBD assessed_VBN by_IN an_DT immunoassay_NN ,_, in_IN which_WDT the_DT live_JJ cells_NNS in_IN the_DT monolayer_NN were_VBD incubated_VBN with_IN a_DT type-common_NN anti-gD_NN rabbit_NN serum_NN ,_, R#7_JJ ,_, and_CC then_RB fixed_VBN and_CC incubated_VBN with_IN a_DT detection_NN system_NN as_IN previously_RB described_VBN ._SENT Comparable_JJ levels_NNS of_IN cell_NN surface_NN expression_NN were_VBD consistently_RB noted_VBN for_IN gD1_JJ ,_, gD2_JJ ,_, all_RB of_IN the_DT gD1/gD2_JJ hybrids_NNS ,_, and_CC all_DT HSV-1_JJ mutants_NNS (_( data_NNS not_RB shown_VBN )_) ,_, indicating_VBG that_IN the_DT differences_NNS in_IN cell_NN fusion_NN observed_VBD could_MD not_RB be_VB explained_VBN by_IN expression_NN levels_NNS of_IN gD_NNS ._SENT The_DT results_NNS presented_VBD here_RB and_CC elsewhere_RB show_VBP that_IN the_DT amino_NN acid_NN sequence_NN in_IN the_DT N-terminal_JJ region_NN of_IN gD_NNS ,_, outside_JJ of_IN the_DT Ig-fold_NN ,_, influences_VBZ whether_IN human_JJ nectin-2_NN and_CC an_DT endogenous_JJ CHO_NP receptor_NN can_MD serve_VB as_IN entry/fusion_NN receptors_NNS ._SENT We_PP showed_VBD here_RB (_( i_NP )_) that_IN gD2_NN is_VBZ more_RBR active_JJ than_IN gD1_NN in_IN inducing_VBG the_DT fusion_NN of_IN cells_NNS expressing_VBG human_JJ nectin-2_NN or_CC only_RB an_DT endogenous_JJ CHO_NP receptor_NN ,_, regardless_RB of_IN whether_IN the_DT viral_JJ glycoproteins_NNS gB_NN ,_, gH_NNS ,_, and_CC gL_NN were_VBD from_IN HSV-1_NP or_CC HSV-2_NP and_CC consistent_JJ with_IN the_DT greater_JJR activity_NN of_IN these_DT receptors_NNS for_IN HSV-2_NP entry_NN ,_, and_CC (_( ii_NNS )_) that_IN as_RB many_JJ as_IN 7_CD amino_NN acid_NN differences_NNS between_IN gD1_JJ and_CC gD2_JJ in_IN the_DT first_JJ 53_CD amino_NN acids_NNS of_IN the_DT N_NP terminus_NN are_VBP largely_RB responsible_JJ for_IN the_DT greater_JJR activity_NN of_IN gD2_NN ._SENT It_PP was_VBD previously_RB shown_VBN that_IN specific_JJ amino_NN acid_NN substitutions_NNS in_IN the_DT N_NP terminus_NN of_IN gD1_NN enable_VBP functional_JJ interactions_NNS with_IN human_JJ nectin-2_NN ._SENT Substitutions_NNS Q27P_NP or_CC Q27R_NP in_IN gD1_NN confer_VBP the_DT ability_NN of_IN HSV-1_NP to_TO use_VB nectin-2_NN as_IN an_DT entry_NN or_CC fusion_NN receptor_NN ._SENT Also_RB ,_, substitution_NN L25P_NN in_IN gD1_NN enables_VBZ HSV-1_NP to_TO use_VB nectin-2_NN as_IN an_DT entry_NN receptor_NN ._SENT Interestingly_RB ,_, the_DT mutations_NNS at_IN position_NN 27_CD were_VBD also_RB shown_VBN to_TO enhance_VB ,_, by_IN about_IN 10-fold_NN ,_, the_DT limited_JJ ability_NN of_IN HSV-1_NP strain_NN KOS_NP to_TO infect_VB CHO_NP cells_NNS ._SENT Other_JJ effects_NNS of_IN the_DT mutations_NNS at_IN position_NN 27_CD in_IN gD1_JJ include_VBP enhanced_JJ affinity_NN of_IN isolated_JJ soluble_JJ mutant_JJ gD1_NN for_IN nectin-1_JJ and_CC significantly_RB reduced_VBN ability_NN of_IN HSV-1_NP to_TO use_VB HVEM_NP as_IN an_DT entry_NN or_CC fusion_NN receptor_NN ,_, a_DT finding_VBG consistent_JJ with_IN the_DT location_NN of_IN amino_NN acid_NN 27_CD in_IN a_DT contact_NN region_NN identified_VBN in_IN the_DT X-ray_NN structures_NNS ._SENT It_PP should_MD be_VB noted_VBN that_IN L25_NP and_CC Q27_NP ,_, and_CC in_IN fact_NN all_RB of_IN the_DT positions_NNS in_IN the_DT contact_NN region_NN from_IN positions_NNS 24_CD to_TO 32_CD ,_, are_VBP identical_JJ in_IN gD1_JJ and_CC gD2_JJ ._SENT Thus_RB ,_, substitutions_NNS at_IN positions_NNS 25_CD or_CC 27_CD enable_VBP gD1_JJ to_TO interact_VB functionally_RB with_IN nectin-2_NN but_CC are_VBP not_RB necessary_JJ for_IN gD2_NN to_TO interact_VB with_IN nectin-2_NN ._SENT Attempts_NNS were_VBD made_VBN to_TO isolate_VB the_DT endogenous_JJ CHO_NP receptor_NN ,_, without_IN success_NN ._SENT Oligonucleotides_NNS matching_VBG conserved_VBN sequences_NNS in_IN nectin-1_NN and_CC nectin-2_NN were_VBD tested_VBN for_IN the_DT ability_NN to_TO prime_JJ amplification_NN of_IN homologous_JJ sequences_NNS from_IN reverse_JJ transcripts_NNS of_IN RNA_NP extracted_VBD from_IN CHO_NP cells_NNS or_CC from_IN plasmids_NNS extracted_VBN from_IN a_DT library_NN of_IN CHO_NP expression_NN clones_NNS ._SENT Antibodies_NNS raised_VBN against_IN human_JJ or_CC mouse_NN nectin-2_NN were_VBD tested_VBN for_IN their_PP$ ability_NN to_TO bind_VB to_TO CHO_NP cells_NNS by_IN immunofluorescence_NN ._SENT Identification_NN of_IN the_DT endogenous_JJ CHO_NP receptor_NN would_MD probably_RB require_VB expression_NN cloning_VBG ,_, which_WDT would_MD in_RB turn_VB require_VB a_DT cell_NN line_NN with_IN a_DT high_JJ level_NN of_IN resistance_NN to_TO HSV-2_NP entry_NN ._SENT Some_DT pilot_NN experiments_NNS done_VBN with_IN the_DT B78H1_NP cell_NN line_NN were_VBD not_RB satisfactory_JJ ._SENT We_PP abandoned_VBD the_DT effort_NN to_TO identify_VB the_DT receptor_NN because_IN the_DT results_NNS obtained_VBN in_IN the_DT present_JJ study_NN were_VBD so_RB similar_JJ for_IN human_JJ nectin-2_NN and_CC the_DT endogenous_JJ CHO_NP receptor_NN ,_, suggesting_VBG that_IN the_DT endogenous_JJ CHO_NP receptor_NN could_MD be_VB the_DT Chinese_JJ hamster_NN homolog_NN of_IN nectin-2_NN despite_IN our_PP$ inability_NN to_TO amplify_VB nectin-2_JJ gene_NN sequences_NNS by_IN PCR_NP ._SENT Human_JJ nectin-2_NN and_CC the_DT endogenous_JJ CHO_NP receptor_NN are_VBP distinct_JJ because_IN certain_JJ mutations_NNS in_IN gD2_NN can_MD inhibit_VB cell_NN fusion_NN to_TO a_DT much_RB greater_JJR extent_NN with_IN control_NN CHO_NP cells_NNS than_IN with_IN CHO_NP cells_NNS expressing_VBG nectin-2_NN ._SENT Although_IN the_DT results_NNS summarized_VBD here_RB indicate_VB that_IN the_DT N-terminal_JJ regions_NNS of_IN gD1_JJ and_CC gD2_JJ influence_NN entry_NN and_CC cell_NN fusion_NN with_IN nectin-2_NN or_CC the_DT endogenous_JJ CHO_NP receptor_NN ,_, further_JJR studies_NNS are_VBP required_VBN to_TO determine_VB whether_IN the_DT N_NP terminus_NN makes_VBZ direct_JJ contact_NN with_IN these_DT receptors_NNS ,_, influences_VBZ the_DT conformation_NN of_IN other_JJ regions_NNS in_IN gD_NNS that_WDT are_VBP involved_VBN in_IN direct_JJ contacts_NNS ,_, or_CC influences_VBZ interactions_NNS with_IN the_DT other_JJ viral_JJ glycoproteins_NNS that_WDT are_VBP required_VBN for_IN cell_NN fusion_NN ._SENT Cell_NN fusion_NN induced_VBN by_IN plasmids_NNS expressing_VBG homologous_JJ or_CC heterologous_JJ mixtures_NNS of_IN the_DT HSV-1_NP or_CC HSV-2_NP glycoproteins_NNS ._SENT Cell_NN fusion_NN induced_VBN by_IN plasmids_NNS expressing_VBG homologous_JJ or_CC heterologous_JJ mixtures_NNS of_IN the_DT HSV-1_NP or_CC HSV-2_NP glycoproteins_NNS ._SENT The_DT cell_NN fusion_NN assay_NN was_VBD performed_VBN by_IN transfecting_VBG CHO_NP effector_NN cells_NNS with_IN plasmids_NNS expressing_VBG the_DT indicated_JJ glycoproteins_NNS or_CC vector_NN alone_RB (_( neg_NN )_) ._SENT The_DT effector_NN cells_NNS were_VBD mixed_VBN with_IN CHO_NP target_NN cells_NNS expressing_VBG only_RB the_DT CHO_NP endogenous_JJ receptor_NN or_CC also_RB nectin-2_JJ ,_, nectin-1_JJ ,_, or_CC HVEM_NP ._SENT Effector_NN cells_NNS transfected_VBN with_IN an_DT homologous_JJ set_NN of_IN HSV-1_NP or_CC HSV-2_NP glycoproteins_NNS are_VBP the_DT controls_NNS ._SENT The_DT glycoprotein_NN substituted_VBN is_VBZ indicated_VBN with_IN a_DT minus_NN (_( -_: )_) ,_, and_CC the_DT substituting_VBG protein_NN is_VBZ indicated_VBN with_IN a_DT plus_NN (_( +_SYM )_) ._SENT Cell_NN fusion_NN was_VBD quantified_VBN by_IN measurements_NNS of_IN luciferase_NN activity_NN (_( arbitrary_JJ units_NNS divided_VBN by_IN 10_CD to_TO give_VB the_DT numbers_NNS shown_VBN on_IN the_DT y_NP axis_NN )_) ._SENT The_DT values_NNS shown_VBN are_VBP means_NNS and_CC standard_JJ deviations_NNS from_IN one_CD experiment_NN performed_VBN in_IN triplicate_NN ._SENT The_DT results_NNS presented_VBN are_VBP representative_JJ of_IN at_IN least_JJS two_CD other_JJ additional_JJ experiments_NNS ._SENT Cell_NN fusion_NN induced_VBN by_IN gD2/1_JJ or_CC gD1/2_JJ hybrid_JJ molecules_NNS in_IN combination_NN with_IN the_DT other_JJ HSV-1_NP or_CC HSV-2_NP glycoproteins_NNS ._SENT Cell_NN fusion_NN induced_VBN by_IN gD2/1_JJ or_CC gD1/2_JJ hybrid_JJ molecules_NNS in_IN combination_NN with_IN the_DT other_JJ HSV-1_NP or_CC HSV-2_NP glycoproteins_NNS ._SENT These_DT hybrids_NNS have_VBP the_DT first_JJ 66_CD amino_NN acids_NNS from_IN gD1_JJ or_CC gD2_JJ and_CC the_DT remainder_NN from_IN gD2_JJ or_CC gD1_JJ ,_, respectively_RB ._SENT The_DT CHO_NP effector_NN cells_NNS were_VBD transfected_VBN with_IN plasmids_NNS expressing_VBG the_DT indicated_JJ glycoproteins_NNS or_CC vector_NN alone_RB (_( neg_NN )_) ._SENT Effector_NN cells_NNS were_VBD mixed_VBN with_IN CHO_NP target_NN cells_NNS expressing_VBG only_RB the_DT CHO_NP endogenous_JJ receptor_NN or_CC also_RB nectin-2_JJ ,_, nectin-1_JJ ,_, or_CC HVEM_NP ._SENT Cell_NN fusion_NN was_VBD quantified_VBN by_IN measurements_NNS of_IN luciferase_NN activity_NN (_( arbitrary_JJ units_NNS divided_VBN by_IN 100_CD to_TO give_VB the_DT numbers_NNS shown_VBN on_IN the_DT y_NP axis_NN )_) ._SENT The_DT values_NNS shown_VBN are_VBP means_NNS and_CC standard_JJ deviations_NNS from_IN one_CD experiment_NN performed_VBN in_IN triplicate_NN ._SENT The_DT results_NNS presented_VBN are_VBP representative_JJ of_IN at_IN least_JJS two_CD other_JJ additional_JJ experiments_NNS ._SENT (_( A_NP )_) Alignment_NN of_IN the_DT 66_CD N-terminal_JJ amino_NN acids_NNS of_IN HSV-1(KOS)_NP gD_NNS and_CC HSV-2(333)_JJ gD_NNS ._SENT (_( A_NP )_) Alignment_NN of_IN the_DT 66_CD N-terminal_JJ amino_NN acids_NNS of_IN HSV-1(KOS)_NP gD_NNS and_CC HSV-2(333)_JJ gD_NNS ._SENT Dots_NNS indicate_VBP identity_NN ._SENT The_DT positions_NNS where_WRB the_DT amino_NN acids_NNS differ_VBP are_VBP indicated_VBN ._SENT (_( B_NP )_) Backbone_NP trace_NN of_IN the_DT crystal_NN structure_NN of_IN gD1_NN bound_VBN to_TO HVEM_NP ._SENT HVEM_NP is_VBZ shown_VBN in_IN black_JJ ,_, and_CC gD1_NN is_VBZ shown_VBN in_IN gray_JJ ._SENT Residues_NNS that_WDT have_VBP been_VBN substituted_VBN in_IN the_DT gD1_JJ mutants_NNS are_VBP displayed_VBN in_IN different_JJ colors_NNS ._SENT Expression_NN plasmids_NNS generated_VBN for_IN this_DT study_NN 